Core Insights - Niagen Bioscience announced results from the first randomized controlled trial demonstrating that daily supplementation with its patented nicotinamide riboside (NR) significantly increased NAD+ levels and improved symptoms of fatigue, depression, and sleep quality in individuals with long COVID [1][3][12] Study Overview - The study involved 58 participants, randomized in a double-blind, placebo-controlled design, led by Dr. Edmarie Guzmán-Vélez [2][9] - Participants received either 2,000 mg/day of Niagen NR for 20 weeks or a placebo for 10 weeks, followed by Niagen NR for an additional 10 weeks [9][10] - The primary endpoint was the change in cognitive performance, while secondary endpoints assessed fatigue, mood, and sleep quality [10] Key Findings - NAD+ levels increased up to 3.1-fold after 5–10 weeks of supplementation, confirming effective NAD+ restoration [14] - Significant within-group improvements were observed in fatigue severity, sleep quality, and depressive symptoms after 10 weeks of Niagen NR supplementation [14] - Although no statistically significant differences were found between the Niagen NR and placebo groups, the study suggests NAD+ restoration as a promising avenue for recovery from long COVID [13][14] Implications for Long COVID - Long COVID is characterized by persistent symptoms such as fatigue, cognitive impairment, and sleep disturbances, affecting a significant number of individuals globally [6][3] - The study highlights the potential of NAD+ augmentation in addressing these symptoms and advancing understanding of recovery mechanisms [4][7] Company Background - Niagen Bioscience, Inc. (NASDAQ: NAGE) is a leader in NAD+ science and healthy aging research, dedicated to advancing healthspan through innovative NAD+-boosting solutions [16][17] - The company emphasizes the importance of NAD+ in cellular energy and repair, particularly in the context of age-related health changes [17][18]